Resumo
Objetivo: Analisar os possíveis fatores de risco, motivos, influência e consequência no desenvolvimento neuropsiquiátrico devido ao uso comórbido de cannabis entre os jovens na atualidade. Métodos: National Library of Medicine (PubMed), Biblioteca Virtual em Saúde (BVS) e Directory of Open Access Journals (DOAJ) foram as bases de dados utilizados para a abordagem metodológica deste estudo. A abordagem metodológica deste trabalho se propôs a um compilado de pesquisa bibliográfica de abordagem qualitativa e caráter descritivo por meio de uma revisão integrada da literatura. Os descritores utilizados foram “schizophrenia”, “cannabis” e “development” utilizando o operador booleano “and”. Os critérios de inclusão foram todos os artigos originais, publicados em inglês, português e espanhol. Resultados: Dos dezesseis artigos foi abordado as possíveis consequências do uso comórbido de cannabis durante a adolescência, tendo: transtorno esquizofrênico, ideações suicidas, depressão e ansiedade como achados. Sendo a esquizofrenia a comorbidade mais prevalente dentre as possíveis influências do canabidiol no sistema neuropsíquico. Considerações finais: Dessa forma, pode-se considerar que o uso de cannabis no período da adolescência realmente possui riscos e uma fisiopatologia a ser estudada em relação a influência do tetra-hidrocarbinol (THC) no Sistema endocanabinóide.
Referências
BLAIR THIES M, et al. Interaction of Cannabis Use Disorder and Striatal Connectivity in Antipsychotic Treatment Response. Schizophr Bull Open, 2020; sgaa014–sgaa014.
BIDZINSKI KK, et al. Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia. npj Schizophrenia 2022; 8(1):1–11.
CARDNO AG, et al. Psychotic‐Like Experiences in Adolescence Occurring in Combination or Isolation: Associations with Schizophrenia Risk Factors. Psychiatr res clin pract, 2021;3(2): 67–75.
GAYER-ANDERSON C, et al. The EUropean Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme. Soc Psychiatry Psychiatr Epidemiol, 2020: 645–657.
GRECHUK K, et al. Cannabis, Schizophrenia Risk and Genetics: A Case Report of a Patient With Homozygous Valine Catechol-O-Methyltransferase Polymorphism. Cureus, 2021: e15740–e15740.
HAFNER H. Psychosis and cannabis. Archives of Clinical Psychiatry 2005: 32(2):53–67.
KARIS K, et al. Altered Expression Profile of IgLON Family of Neural Cell Adhesion Molecules in the Dorsolateral Prefrontal Cortex of Schizophrenic Patients. Frontiers in Molecular Neuroscience, 2018: 11.
MANUAL DO MINISTÉRIO DE SAÚDE. 2020. Disponível em: https://aps.saude.gov.br/noticia/11997. Acessado em: 3 de abril de 2022.
MUZAFFAR A, et al. Clinical Investigation on the Impact of Cannabis Abuse on Thyroid Hormones and Associated Psychiatric Manifestations in the Male Population. Frontiers in Psychiatry, 2021: 12.
NEILL E, et al. Examining which factors influence age of onset in males and females with schizophrenia. Schizophr Res, 2020: 265–270.
OUANOUCHE EH, et al. Cannabis and schizophrenia: characterisation of a risk factor in a sample of Moroccan patients hospitalised for psychosis. Middle East Current Psychiatry, 2022; 29(1): 1–8.
RASMUSSEN JØ, et al. Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial. BMC Psychiatry, 2021; 404–404.
RENTERO D, et al. Cannabis-induced psychosis: clinical characteristics and its differentiation from schizophrenia with and without cannabis use. Adicciones, 2021; 95–108.
RODRIGO C, et al. A retrospective analysis of cannabis use in a cohort of mentally ill patients in Sri Lanka and its implications on policy development. Substance Abuse Treatment, Prevention, and Policy, 2010: 5(1): 16.
TAO R, et al. Cannabinoid receptor CNR1 expression and DNA methylation in human prefrontal cortex, hippocampus and caudate in brain development and schizophrenia. Transl Psychiatry, 2020: 158–158.
UHER R, et al. A familial risk enriched cohort as a platform for testing early interventions to prevent severe mental illness. BMC Psychiatry, 2014; 14(1): 344.
ZHORNITSKY S, et al. Psychopathology in Substance Use Disorder Patients with and without Substance-Induced Psychosis. Journal of Addiction, 2015; 2015: e843762.
